inactiviteit loss of muscle mass muscle atrophy
Conditions
Interventions
Study A: During a single test day, subjects will undergo continuous intravenous
tracer infusions of labelled amino acids, and subjects ingest a beverage
containing 25 gram intrinsically labelled whe
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Substudy A: -Normal weight (BMI 19-25 kg/m2) -Middle-aged (age 30-55 yrs);Substudy B: -Males -Young to middle-aged (18-35 yrs);Substudy C: -Males -Middle-aged (30-55 yrs) -Extreme obesity (BMI >35 kg/m2) -Scheduled for bariatric bypass surgery
Exclusion criteria
Exclusion criteria: Substudy A: - Currently smoking cigarettes or tobacco - Allergies to milk proteins (whey or casein) - A history of neuromuscular problems -Diagnosed impaired renal (kidney stones, nephritis, nephritic syndrome, end-stage renal disease) or liver function (acute or chronic hepatitis, alcoholic liver disease, liver cirrhosis). - Use of medications known to affect digestion and/or absorption (antacids, H-2-receptor blockers, proton pump inhibitors, NSAID*s) 7 days prior to the experimental test-day. - Use of anticoagulants, blood diseases, allergy for lidocain. - Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications). - Participation in regular exercise for >3 week or >150 min/week. - Type 2 diabetes (according to OGTT).;Substudy B: - Currently smoking cigarettes or tobacco - Allergies to milk proteins (whey or casein) - Arthritic conditions - A history of neuromuscular problems - Diagnosed impaired renal or liver function - Diagnosed impaired renal (kidney stones, nephritis, nephritic syndrome, end-stage renal disease) or liver function (acute or chronic hepatitis, alcoholic liver disease, liver cirrhosis) - Use of medications known to affect digestion and/or absorption (antacids, H-2-receptor blockers, proton pump inhibitors, NSAID*s) 7 days prior to the experimental test-day - Use of anticoagulants, blood diseases, allergy for lidocain - Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications). -History with deep venous thrombosis or pulmonary embolie. -Participation in regular exercise for >3 week or >150 min/week. -Type 2 diabetes (HbA1c>6.5%).;Substudy C: - Allergies to milk proteins (whey or casein) - A history of neuromuscular problems - Diagnosed impaired renal or liver function - Use of anticoagulants, blood diseases, allergy for lidocain - Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications). - Participation in regular exercise for >3 week or >150 min/week. - Diagnosed type 2 diabetes, and/or use of blood glucose lowering medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint for all studies: Basal and postprandial muscle protein synthesis rates, expressed as fractional synthetic rate (FSR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: Rate of protein digestion and absorption. | — |
Countries
Netherlands
Outcome results
None listed